Topics in Companion Animal Medicine
Volume 24, Issue 3 , Pages 122-129, August 2009

Supporting the Veterinary Cancer Patient on Chemotherapy: Neutropenia and Gastrointestinal Toxicity

  • David M. Vail, DVM, DACVIM (Oncology)

      Affiliations

    • Corresponding Author InformationAddress reprint requests to: David M. Vail, DVM, DACVIM (Oncology), University of Wisconsin–Madison, School of Veterinary Medicine, 2015 Linden Dr, Madison, WI 53706

University of Wisconsin–Madison, School of Veterinary Medicine, Madison, WI, USA

The application of effective chemotherapy protocols in companion animals with sensitive tumors may result in return to a good quality of life and extended long-term survival. However, the potential for adding adverse events that impact overall quality of life in veterinary cancer patients is an important consideration. To ensure the experience is a positive one for our clients and patients alike, the practicing veterinary oncologist must ensure clients are appropriately educated as to the type and likelihood of adverse events that may occur in their companions and should plan for appropriate preventative and therapeutic protocols to manage them. Such attention to detail will help guarantee their clients' experience with medical treatment is positive and worthwhile, and will result in improvement in the well-being of their companion.

Keywords: adverse events, cat, chemotherapy, dog

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Author disclosure of potential conflicts of interest: The author has received research funding and is a paid consultant for Pfizer Animal Health, Inc.

PII: S1938-9736(09)00015-4

doi:10.1053/j.tcam.2009.02.004

Topics in Companion Animal Medicine
Volume 24, Issue 3 , Pages 122-129, August 2009